News | August 08, 2025
Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Capricor’s BLA for Deramiocel received Priority Review in March 2025
To streamline complex medical writing workflows with GenAI
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
Subscribe To Our Newsletter & Stay Updated
